Adcetris (brentuximab vedotin) [product monograph]. HC.

Regulatory approval published by the Health Canada.

Citation

Seagen Inc. Adcetris (brentuximab vedotin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080158.PDF. Published April 2025. Accessed June 2025.

View API

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication Statements
ADCETRIS is indicated for the treatment of previously untreated adult patients with systemic anaplastic large cell lymphoma (sALCL), peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) or angioimmunoblastic T-cell lymphoma (AITL), whose tumours express CD30, in combination with cyclophosphamide, doxorubicin, and prednisone (CHP). 3
ADCETRIS is indicated for the treatment of adult patients with CD30-expressing MF who have received prio systemic therapy 1

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) CD30 + Anaplastic Large Cell Lymphoma Brentuximab vedotin, Cyclophosphamide, Doxorubicin, Prednisone
Sensitivity (+) CD30 + Angioimmunoblastic T-Cell Lymphoma Brentuximab vedotin, Cyclophosphamide, Doxorubicin, Prednisone
Sensitivity (+) CD30 + Peripheral T-Cell lymphoma, NOS Brentuximab vedotin, Cyclophosphamide, Doxorubicin, Prednisone
Sensitivity (+) CD30 + Mycosis Fungoides Brentuximab vedotin, Cyclophosphamide, Doxorubicin, Prednisone